Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Distinct association between aberrant methylation of Wnt inhibitors and genetic alterations in acute myeloid leukaemia.

Hou HA, Kuo YY, Liu CY, Lee MC, Tang JL, Chen CY, Chou WC, Huang CF, Lee FY, Liu MC, Yao M, Tien HF.

Br J Cancer. 2011 Dec 6;105(12):1927-33. doi: 10.1038/bjc.2011.471. Epub 2011 Nov 17.

2.

Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia.

Jost E, Schmid J, Wilop S, Schubert C, Suzuki H, Herman JG, Osieka R, Galm O.

Br J Haematol. 2008 Sep;142(5):745-53. doi: 10.1111/j.1365-2141.2008.07242.x. Epub 2008 Jun 3.

PMID:
18537968
3.

Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.

Griffiths EA, Gore SD, Hooker C, McDevitt MA, Karp JE, Smith BD, Mohammad HP, Ye Y, Herman JG, Carraway HE.

Leuk Lymphoma. 2010 Sep;51(9):1711-9. doi: 10.3109/10428194.2010.496505.

4.

C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics.

Lu Y, Chen W, Chen W, Stein A, Weiss LM, Huang Q.

Am J Hematol. 2010 Jun;85(6):426-30. doi: 10.1002/ajh.21706.

5.

Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia.

Valencia A, Román-Gómez J, Cervera J, Such E, Barragán E, Bolufer P, Moscardó F, Sanz GF, Sanz MA.

Leukemia. 2009 Sep;23(9):1658-66. doi: 10.1038/leu.2009.86. Epub 2009 Apr 23.

PMID:
19387464
6.

Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS.

Reins J, Mossner M, Neumann M, Platzbecker U, Schumann C, Thiel E, Hofmann WK.

Leuk Res. 2010 Dec;34(12):1610-6. doi: 10.1016/j.leukres.2010.04.013. Epub 2010 May 14.

PMID:
20471677
7.

WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors.

Pannone G, Bufo P, Santoro A, Franco R, Aquino G, Longo F, Botti G, Serpico R, Cafarelli B, Abbruzzese A, Caraglia M, Papagerakis S, Lo Muzio L.

Oncol Rep. 2010 Oct;24(4):1035-41.

PMID:
20811686
8.

Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas.

Götze S, Wolter M, Reifenberger G, Müller O, Sievers S.

Int J Cancer. 2010 Jun 1;126(11):2584-93. doi: 10.1002/ijc.24981.

9.

Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.

Szankasi P, Ho AK, Bahler DW, Efimova O, Kelley TW.

Leuk Res. 2011 Feb;35(2):200-7. doi: 10.1016/j.leukres.2010.09.018. Epub 2010 Oct 20.

PMID:
20970189
10.

Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia.

Cheng CK, Li L, Cheng SH, Ng K, Chan NP, Ip RK, Wong RS, Shing MM, Li CK, Ng MH.

Blood. 2011 Dec 15;118(25):6638-48. doi: 10.1182/blood-2011-05-354712. Epub 2011 Oct 26.

11.

Preferential hypermethylation of the Dickkopf-1 promoter in core-binding factor leukaemia.

Suzuki R, Onizuka M, Kojima M, Shimada M, Fukagawa S, Tsuboi K, Kobayashi H, Shintani A, Ogawa Y, Kawada H, Hotta T, Ando K.

Br J Haematol. 2007 Sep;138(5):624-31.

PMID:
17686056
12.

Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features.

Chauhan PS, Bhushan B, Mishra AK, Singh LC, Saluja S, Verma S, Gupta DK, Mittal V, Chaudhry S, Kapur S.

Med Oncol. 2011 Jun;28(2):544-51. doi: 10.1007/s12032-010-9485-4. Epub 2010 Mar 31.

PMID:
20354824
13.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group..

N Engl J Med. 2008 May 1;358(18):1909-18. doi: 10.1056/NEJMoa074306.

14.

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.

Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, Huang CF, Lee FY, Liu MC, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Lin LI, Tien HF.

Blood. 2009 Dec 17;114(26):5352-61. doi: 10.1182/blood-2009-05-223784. Epub 2009 Oct 6.

15.

Hypermethylation and aberrant expression of Wnt-antagonist family genes in gastric cardia adenocarcinoma.

Guo Y, Guo W, Chen Z, Kuang G, Yang Z, Dong Z.

Neoplasma. 2011;58(2):110-7.

PMID:
21275459
16.

Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia.

Chim CS, Wong AS, Kwong YL.

Br J Haematol. 2002 Dec;119(4):988-90.

PMID:
12472578
17.

[The role of secreted Wnt-antagonist genes hypermethylation in early detection of colorectal tumor].

Qi J, Zhu YQ, Luo J, Tao WH.

Zhonghua Yi Xue Za Zhi. 2007 Jul 24;87(28):1954-7. Chinese.

PMID:
17923031
18.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020
19.

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K.

J Clin Oncol. 2010 Feb 1;28(4):570-7. doi: 10.1200/JCO.2008.21.6010. Epub 2009 Dec 28.

PMID:
20038735
20.

Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.

Steudel C, Wermke M, Schaich M, Schäkel U, Illmer T, Ehninger G, Thiede C.

Genes Chromosomes Cancer. 2003 Jul;37(3):237-51.

PMID:
12759922

Supplemental Content

Support Center